Plasmapheresis vs EBOO: Understanding the Difference

Both plasmapheresis and EBOO are extracorporeal procedures - meaning blood leaves the body, undergoes a process, and returns. That surface similarity leads many people to search plasmapheresis vs EBOO, expecting to find two roughly equivalent "blood purification" options. In practice, the two procedures differ fundamentally: in what they do to blood, in the body of evidence supporting them, and in the regulatory and clinical contexts in which each is used.

This article explains how each procedure works, what the current evidence shows, and why the comparison matters for anyone weighing blood-based therapies for health optimization or clinical treatment.

What Is Plasmapheresis (Therapeutic Plasma Exchange)?

Plasmapheresis, in its therapeutic form - properly called therapeutic plasma exchange (TPE) - is a large-volume procedure in which plasma is separated from blood cells, discarded, and replaced with a substitute fluid such as human albumin or fresh frozen plasma (FFP). A single session typically processes one to one-and-a-half times the patient's total plasma volume.

The goal is the removal of pathological substances circulating in plasma: autoantibodies, immune complexes, inflammatory cytokines, and pathological proteins that drive disease processes. As the 2023 Core Curriculum from the American Journal of Kidney Diseases describes it, TPE "entails removing plasma from the patient in exchange for replacement fluid" - a distinction that separates it from simple plasma removal without replacement (Cervantes, Bloch & Sperati, AJK, 2023).

Two physical methods accomplish plasma separation: centrifugation, in which whole blood spins at high speed to separate components by density, and membrane filtration, in which blood passes through a hollow-fiber membrane that allows plasma to cross while retaining cells. Both are used in clinical practice; centrifugation is more common globally.

The clinical evidence base for TPE is well-established. The American Society for Apheresis (ASFA) 9th edition guidelines (2023) identify 166 therapeutic apheresis indications, 118 of which include TPE. Category I (first-line) indications include thrombotic thrombocytopenic purpura (TTP), Guillain-Barré syndrome (GBS), myasthenia gravis crisis, and anti-GBM (Goodpasture) disease (Connelly-Smith et al., Journal of Clinical Apheresis, 2023).

In longevity medicine, TPE has attracted growing research interest. A 2025 randomized placebo-controlled trial from the Buck Institute and Circulate Health found that TPE alone reduced biological age by 1.32 years by multi-omic biomarkers; TPE combined with IVIG produced a 2.61-year reduction - the first clinical trial demonstrating measurable biological age rejuvenation via plasma exchange in healthy adults over 50 (Fuentealba et al., Aging Cell, 2025).

What Is EBOO?

Extracorporeal blood oxygenation and ozonation (EBOO) is a procedure in which blood is circulated outside the body through a dialyzer-type membrane and exposed to a mixture of oxygen and ozone gas. Unlike TPE, no plasma is removed; the aim is to subject blood to a controlled oxidative stimulus. Modern systems marketed as EBO2 add UV light irradiation to the circuit.

The proposed mechanism involves ozone reacting with blood components to generate a carefully titrated oxidative stress response. This activates the Nrf2 cellular defense pathway, upregulates antioxidant enzymes including superoxide dismutase (SOD) and catalase, and reduces pro-inflammatory cytokines such as IL-1, IL-6, and TNF-α (El Meligy, Elemam & Talaat, Dentistry Journal, 2023). EBOO processes substantially larger blood volumes per session - up to 4,800 mL - than traditional autohemotherapy (approximately 250 mL), which proponents argue produces a more systemic effect.

The procedure was first described in humans by Di Paolo and colleagues in a 2000 preliminary report and later evaluated in a controlled trial for peripheral artery disease (Di Paolo et al., NT J Artif Organs, 2000; Di Paolo et al., Int J Artif Organs, 2005).

Plasmapheresis vs EBOO: Key Differences

Feature

Therapeutic Plasma Exchange (TPE)

EBOO

What it does to blood

Removes and replaces large plasma volume

Exposes circulating blood to ozone/oxygen mix

Primary mechanism

Removes pathological constituents (autoantibodies, cytokines, proteins)

Oxidative stimulus → antioxidant activation

Replacement fluid required

Yes (albumin or FFP)

No

Volume processed

1–1.5× total plasma volume

Up to 4,800 mL blood per session

Regulatory status (US)

FDA-cleared apheresis devices; ASFA-recognized

No FDA approval for specific conditions; no ASFA listing

Clinical evidence grade

ASFA Category I–IV across 118 indications

Preliminary; no large-scale RCTs

Clinical setting

Hospital or apheresis center

Wellness and integrative medicine clinics

The clearest difference is regulatory and evidentiary. ASFA's 9th edition guidelines contain no listed indications for EBOO; ozone therapy is not a recognized therapeutic apheresis modality in any major international apheresis society's current guidelines (Connelly-Smith et al., JCA, 2023).

What Does the Evidence Show?

Evidence for Therapeutic Plasma Exchange

TPE has the most robust evidence base of any extracorporeal blood-based therapy. Decades of clinical trials, retrospective cohort data, and guideline development support its use across neurological, hematological, and autoimmune conditions. For Category I indications, real-world cohort data show meaningful response rates - 75% complete response in TTP, for example, in a 234-patient single-center study (Dogan & Aydeniz, PJMS, 2025). In longevity applications, the 2025 Buck Institute RCT provides the first controlled human evidence of measurable biological age reduction.

Evidence for EBOO

Evidence for EBOO specifically is limited. A 2023 systematic evidence and gap map covering ozone therapy broadly found positive or potentially positive effects in 177 of 334 intervention-outcome associations, but noted key gaps: limited high-quality RCTs, no standardized protocols, and lack of long-term efficacy data (Serra et al., Frontiers in Public Health, 2023). An observational study of 218 patients receiving systemic ozone therapy reported significant improvements in quality-of-life measures, but without a control group, a placebo contribution cannot be excluded (Martinelli & Romanello, Cureus, 2024).

No large-scale randomized controlled trials have been conducted specifically on EBOO. The FDA has not approved EBOO or EBO2 for any specific medical condition. Proponents of EBOO acknowledge these evidence gaps.

Safety Considerations

TPE is generally well-tolerated in trained clinical settings. Commonly reported adverse events include transient hypotension (~19% of procedures), citrate-related hypocalcemia (tingling, cramps), hypothermia from large-volume fluid infusion, and catheter-related complications with central line placement. Serious adverse events are uncommon - a complication rate of approximately 9% was observed across 234 patients in recent cohort data (Dogan & Aydeniz, 2025).

EBOO has not shown serious adverse effects in reviewed studies. Ozone therapy carries established contraindications, including glucose-6-phosphate dehydrogenase (G6PD) deficiency, hyperthyroidism, and pregnancy. Because EBOO is not FDA-cleared and is offered primarily in wellness settings, procedural standardization varies across providers.

Frequently Asked Questions

Is EBOO the same as plasmapheresis?

No. EBOO vs plasmapheresis involves two different mechanisms: plasmapheresis removes pathological plasma constituents via large-volume plasma exchange with replacement fluid; EBOO exposes circulating blood to ozone and oxygen without removing plasma. The two procedures have different evidence bases, regulatory statuses, and clinical settings.

Which has more clinical evidence - plasmapheresis or EBOO?

Therapeutic plasma exchange has substantially more clinical evidence. The ASFA 9th edition (2023) lists 118 indications for TPE with graded categories of evidence. EBOO has no ASFA listing and no large-scale RCTs for any specific condition.

What does EBOO therapy do?

EBOO circulates blood extracorporeally through a membrane where it contacts an ozone/oxygen mixture. The proposed effect is a controlled oxidative stimulus that activates antioxidant pathways and reduces inflammatory cytokines. Clinical evidence for specific outcomes remains limited.

Can EBOO replace plasma exchange?

No. EBOO therapy vs plasma exchange are not interchangeable. TPE is the standard of care for specific conditions (TTP, GBS, myasthenia gravis crisis) and is supported by guideline-grade evidence. EBOO does not remove pathological plasma proteins and is not used in these clinical contexts.

Is EBOO vs plasmapheresis a relevant comparison for longevity?

Both have been positioned in wellness and longevity settings, but their evidence profiles differ significantly. TPE has a 2025 randomized controlled trial demonstrating measurable biological age reduction in healthy adults. EBOO lacks comparable controlled trial data in longevity-specific outcomes.

Key Takeaways

• Plasmapheresis vs EBOO: fundamentally different procedures - TPE removes pathological plasma constituents; EBOO applies an oxidative ozone stimulus without removing plasma
• TPE has 118 ASFA-graded clinical indications and decades of trial data; EBOO has no ASFA listing and no large-scale RCTs
• The 2025 Buck Institute RCT is the first controlled human evidence for biological age reduction via therapeutic plasma exchange
• EBOO shows signals in observational and small-study data but lacks regulatory approval and high-quality controlled trials
• Safety profiles differ: TPE has well-characterized, manageable adverse events; EBOO has not shown serious adverse effects but lacks standardized protocols across providers

At Humanaut Health, therapeutic plasma exchange is performed by trained clinical staff as part of an individualized longevity protocol.